Detail of the session
Type :
E-POSTER
E-POSTER
Session Title :
E-Poster Area
Room :
E-POSTERS' AREA
Topic: Atopic Dermatitis – pathogenesis
P100
ATOPIC LABIAL PIGMENTATION: A NEW DIAGNOSTIC FEATURE IN ASIAN PATIENTS WITH ATOPIC DERMATITIS
P101
ATYPICAL HAND, FOOT, AND MOUTH DISEASE CAUSED BY COXSACKIEVIRUS A6 IN CHILDREN WITH ATOPIC DERMATITIS
Topic: Clinical guidelines and recommendations for the treatment of inflammatory skin diseases
P102
TREAT TO TARGET IN PSORIASIS: A BELGIAN DEFINITION OF AN OUTCOME SCORE
Topic: Clinical trials in inflammatory skin diseases
P103
INCIDENCE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS TREATED WITH TILDRAKIZUMAB: POOLED ANALYSIS FROM A PHASE 2 AND TWO PHASE 3 TRIALS
P104
IMPROVEMENT IN ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE THROUGH 3 YEARS OF CONTINUOUS TREATMENT WITH GUSELKUMAB IN THE VOYAGE 1 TRIAL
P105
LONG-TERM SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS
P106
UNDERSTANDING TREATMENT EFFICACY USING PATIENT-LEVEL PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORES FROM RESURFACE 1 AND RESURFACE 2 PHASE 3 TRIALS
P107
ACHIEVING AND MAINTAINING LONG-TERM OPTIMAL IMPROVEMENTS IN PATIENT-REPORTED SYMPTOMS, SIGNS, AND QUALITY OF LIFE AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH GUSELKUMAB: 3-YEAR DATA FROM VOYAGE 1
P108
MAINTENANCE OF RESPONSE WITH GUSELKUMAB FOR UP TO 3 YEARS’ TREATMENT IN THE PHASE 3 VOYAGE 1 TRIAL OF PATIENTS WITH PLAQUE PSORIASIS
P109
IMPACT OF QUALITY OF LIFE AFTER WITHDRAWAL AND RETREATMENT WITH IXEKIZUMAB: A POST HOC ANALYSIS OF A JAPANESE STUDY ON PATIENTS WITH PLAQUE PSORIASIS (UNCOVER-J)
P110
THE EFFICACY OF A GAIN-SWITCHED 311-NM TI:SAPPHIRE LASER IN TREATMENT OF PALMOPLANTAR PUSTULOSIS (PPP)
P111
BENEFITS OF ACHIEVING OF PATIENT-REPORTED SYMPTOM-FREE STATUS VS PASI 100 RESPONSE: ANALYSIS FROM THE VOYAGE-2 CLINICAL TRIAL
P112
RELATIONSHIP BETWEEN PASI AND DLQI SCORES AND ANXIETY/DEPRESSION IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH BRODALUMAB IN THE AMAGINE-1 TRIAL
P113
CORRELATION AND DIFFERENTIATION BETWEEN THE PSORIASIS SYMPTOM INVENTORY (PSI), PSORIASIS AREA AND SEVERITY INDEX (PASI), AND DERMATOLOGY LIFE QUALITY INDEX (DLQI)
P114
CONSISTENCY OF RESPONSE MAINTAINED ACROSS DEMOGRAPHIC SUBGROUPS OF PSORIASIS PATIENTS TREATED WITH GUSELKUMAB FOR UP TO 3 YEARS IN THE VOYAGE 1 AND 2 TRIALS
P115
LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE RESPONDERS AT WEEK 28: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS
P116
NAIL OUTCOME IMPROVEMENTS WITH CERTOLIZUMAB PEGOL IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALS
P117
EFFICACY OF CONTINUED CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WHO INADEQUATELY RESPOND IN THE FIRST 16 WEEKS: RESULTS FROM THE CIMPACT TRIAL
P118
ASSOCIATIONS BETWEEN IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE: RESULTS FROM VOYAGE 2
P119
LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE PARTIAL RESPONDERS OR NON-RESPONDERS TO ETANERCEPT: RESULTS FROM THE RESURFACE 2 PHASE 3 TRIAL THROUGH 148 WEEKS
Topic: Clinics in inflammatory skin disease
P120
LUPUS PERNIO WITH 5 YEARS OF DECREASED VISUAL ACUITY
P121
CHILDHOOD PSORIASIS : A DESCRIPTIVE STUDY
122
ATYPICAL PITYRIASIS ROSEA PRESENTING WITH VESICULAR LESIONS
P123
FACIAL PSORIASIS IN CHILDHOOD
P124
LUPUS VULGARIS M.H 15 YEAR OLD FEMALE SWEDA SYRIA THE COMPLAIN BEGAN SEVEN YEARS AGO WITH CHRONIC ULCERS WITH FACIAL ERYTHMA AND UPPER LIP ENLARGEMENT.
Topic: Comorbidities in inflammatory skin diseases
P125
INCREASE OF CARDIOVASCULAR RISK IN THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
P126
PERIODONTAL DISEASE IN CHILEAN PSORIATIC PATIENTS AND S100A8 MOLECULAR ANALYSIS IN GINGIVAL CREVICULAR FLUID.
P127
CENTRAL OBESITY IN JUVENILE PSORIASIS
P128
OVERWEIGHT IN CHILDHOOD PSORIASIS: A CASE-CONTROL STUDY
P129
CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF HIV-PSORIASIS CASES
P130
DETERMINING SURGICAL VERSUS NONSURGICAL OPTIONS FOR AN UNKNOWN INFLAMMATORY DISORDER IN A CHARCOT FOOT PATIENT
Topic: Eczema
P131
UPADACITINIB IMPROVED PATIENT-REPORTED SLEEP IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Topic: Epidemiology
P132
PUSTULAR PSORIASIS IN TUNISIA : A 10-YEAR REVIEW
P133
VALIDITY OF DIAGNOSTIC CODES FOR IDENTIFICATION OF PSORIASIS PATIENTS IN KOREA
Topic: Health economics and practice organization in inflammatory skin diseases
P134
COST EFFECTIVENESS ANALYSIS OF BIOLOGICS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN HONG KONG
Topic: Other
P135
HIDRADENITIS SUPPURATIVA HURLEY II/III: HISTOPATHOLOGICAL EVALUATION IN 26 PATIENTS
P136
EFFECTS OF SOD3-MSC IN A MURINE ATOPIC DERMATITIS-LIKE SKIN INFLAMMATION MODEL
P137
MELANOMA AND SQUAMOUS CELL CARCINOMA IN PATIENT WITH SEVERE PUSTULAR PSORIASIS
P138
TNF-ALPHA, IL-6 AND IL-8 IN PATIENTS WITH IDIOPATHIC TYPE OF KAPOSI'S SARCOMA
Topic: Patient education
P139
EDUCATION FOR PATIENTS WITH PSORIASIS IN KOREA
Topic: Psoriasis – pathogenesis
P140
CHILHOOD PSORIASIS : A STUDY OF 306 CASES FROM SOUTH TUNISIA
P141
TREATMENT WITH TNF-Α INHIBITOR RECTIFIES M1 MACROPHAGE POLARIZATION FROM BLOOD CD14+ MONOCYTES IN PATIENTS WITH PSORIASIS INDEPENDENT OF STAT1 AND IRF-1 ACTIVATION
P142
TRANSCRIPTOMIC ANALYSIS OF EARLY RESPONSE TO IXEKIZUMAB TREATMENTS IN CHINESE PSORIATIC PATIENTS
P143
INTERACTION BETWEEN MUCOSAL AND CUTANEOUS IMMUNE RESPONSES TO STREPTOCOCCUS PYOGENES IN PSORIASIS: A ROLE FOR ANTIGEN SPECIFIC IGA AND CLA+ T CELLS
P144
THE IL17F HIS161ARG POLYMORPHISM POTENTIALLY AFFECTS SUSCEPTIBILITY OF PSORIASIS THROUGH INCREASED PRODUCTION OF INTERLEUKIN-17F
P145
CLINICAL FEATURES AND FREQUENCY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PSORIATIC PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS
P146
MANAGEMENT OF PUSTULAR PSORIASIS DURING PREGNANCY: REPORT OF 3 CASES
P147
PSORIASIS AND COMORBIDITIES
P148
CHLORPROMAZINE-INDUCED KOEBNER PHENOMENON IN PSORIASIS
P149
A CASE OF GENERALIZED PUSTULAR PSORIASIS RELATED TO ORAL TERBINAFINE
P150
PUSTULAR PSORIASIS AND TELOGEN EFFLUVIUM: WHICH IS INCRIMINATED THE DRUG OR THE DISEASE?
P151
PEDIATRIC GENERALIZED PUSTULAR PSORIASIS: A SEVERE SKIN CONDITION
P152
TISSUE EXPRESSION OF AQUAPORIN 3 IN PSORIATIC PATIENTS BEFORE VS. AFTER TREATMENT WITH ORAL RETINOIDS AND PHOTOCHEMOTHERAPY
P153
THE PILOT STUDY OF HLA-CW06 ALLELE FREQUENCY IN LITHUANIAN PATIENTS WITH PLAQUE PSORIASIS
P154
LINK BETWEEN PSORIASIS AND TUBERCULOSIS
P155
A RARE CASE OF AMOXICILLIN INDUCED PSORIASIS
P156
ONYCHOMADESIS SECONDARY TO INFECTION AND ORAL RETINOIDS IN A PSORIATIC PATIENT
P174
WHOLE EXOME SEQUENCING-BASED APPROACH IDENTIFIED NEW SUSCEPTIBILITY LOCI FOR PSORIASIS IN KOREAN POPULATION
P157
TRANSIENT PHOTOTOXIC SKIN REACTION IN PSORIATIC PATIENT TREATED WITH SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR WITHOUT DISCONTINUING THE USE OF SYSTEMIC DRUGS
P158
HEPATIC AND MUSCULOSKELETAL DISEASE IN PSORIASIS
Topic: Psychological/Social impact of inflammatory skin diseases
P159
SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR (BMS-986165) IMPACT ON QUALITY OF LIFE (QOL) IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PSO) IN A PHASE 2 TRIAL AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
P160
A CASE OF SUICIDE IN A SEVERE PSORIASIS PATIENT EXACERBATED AFTER PHOTOTHERAPY
Topic: Scoring and monitoring the severity of inflammatory diseases
P161
PSORIASIS SEVERITY CALCULATION AND NEW SPANISH COMORBIDITY SCREENING ALGORITHM EASED BY A SMARTPHONE APP. OPTIMISATION OF TIME IN DERMATOLOGIC CONSULTATION
P162
EFFICACY OF SECUKINUMAB IN BOTH BIOLOGIC-NAIVE OR NON-NAIVE PSORIASIS PATIENTS: POST-HOC FINDINGS FROM THE IPSI PSO STUDY
P163
EVALUATION OF THE SECUKINUMAB EFFICACY IN SPECIFIC PSORIASIS LOCATIONS USING THE PSORIASIS SIMPLIFIED INDEX
P164
PSORIASIS SYMPTOM INVENTORY (PSI) TO ASSESS THE SEVERITY OF PLAQUE PSORIASIS SYMPTOMS AND DIFFERENCES IN PATIENT-REPORTED OUTCOMES BETWEEN BRODALUMAB AND USTEKINUMAB
Topic: Psoriasis Arthritis
P165
BIOLOGIC THERAPY OF PSORIASIS IN HAEMODIALYZED PATIENTS
P166
USE OF SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN KOREA
P167
RESPONSE OF SUPERIMPOSED LINEAR PSORIASIS TO ADALIMUMAB
P168
EFFECTIVITY OF ADALIMUMAB. A REAL-LIFE, LONG-TERM STUDY
P168
CHOLESTASIS IN PSORIASIS: A THERAPEUTIC CHALLENGE
P169
CHOLESTASIS IN PSORIASIS: A THERAPEUTIC CHALLENGE
P170
DIAGNOSIS OF PSORIASIS FROM KOEBNER PHENOMENON
P171
INFECTIONS IN LIBYAN PATIENTS UNDER IMMUNOSUPPRESSIVE DRUGS
P173
LOW DOSE NALTREXONE THERAPY FOR PSORIASIS: OPEN-LABEL CASE SERIES
Topic: Late submissions
P175
SECUKINUMAB IS ASSOCIATED WITH SUSTAINED IMPROVEMENT IN PATIENTS’ QUALITY OF LIFE UP TO YEAR 5: RESULTS OF A RANDOMIZED EXTENSION OF THE PHASE III ERASURE AND FIXTURE TRIALS
P176
NOVEL ANTI-INFLAMMATORY EMOLLIENT GEL: ASSESSMENT OF EFFICACY IN SLS PROVOKED/IRRITATED SKIN
P177
CHIKUNGUNYA, DENGUE AND ZIKA INFECTIONS EXACERBATE PSORIASIS IN PATIENTS UNDER BIOLOGICAL THERAPY
P178
THE INFLAMATORY MARKERS AND THE CORONARY ARTERIES DISEASES IN PSORIATIC PATIENTS
P179
EVALUATION OF MICROALBUMINURIA AS AN INDICATOR OF RENAL IMPAIRMENT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
P180
PREVALENCE OF HASHIMOTO'S THYROIDITIS IN PATIENTS WITH PSORIASIS AND ITS ASSOCIATION WITH TYPE AND FORM OF THE DISEASE
P181
CHARACTERISTICS OF PATIENTS WITH PSORIASIS IN A DERMATOLOGY CENTER IN BOGOTÁ COLOMBIA.
P182
ANNUAL ECONOMIC BURDEN OF MEDICAL ATENTION IN PATIENTS WITH MODERATE AND SEVERE ATOPIC DERMATITIS IN A THIRD LEVEL HOSPITAL IN MEXICO CITY: A PRELIMINAR REPORT
P183
MICROSCOPIC EXAMINATION OF NAIL CLIPPINGS FROM PATIENTS WITH PALMOPLANTAR PUSTULOSIS.
P184
PSORIASIS TREATMENT AND PATIENTS SATISFACTION IN CLINICAL PRACTICE
P185
CO-ENCAPSULATION OF IMMUNO-ACTIVE AND ANTI-INFLAMMATORY MOLECULES IN A PICKERING EMULSION FOR ATOPIC DERMATITIS THERAPEUTIC APPROACH
P186
PERIODONTAL DYSBIOSIS IN PLAQUE PSORIASIS PATIENTS
P187
EXPRESSION OF METALLOPROTEASES AND HEPARANASES IN PSORIASIS
P188
SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS: INDIVIDUAL PATIENT META-ANALYSIS OF FOUR PHASE 3 TRIALS IN 2049 PATIENTS
P189
SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN ACTIVE PSORIATIC ARTHRITIS PATIENTS: 52-WEEK RESULTS FROM FUTURE 5 STUDY
P190
PERSPECTIVES OF COLOMBIAN PATIENTS WITH PSORIASIS ON ACCESS TO TREATMENT AND ITS REPERCUSSION ON THE SOCIAL ENVIRONMENT. AN EXPERIENCE OF FUNDAPSO.
P191
PATIENT WITH PSORIASIS, PSORIATIC ARTHRITIS AND HIDRADENITIS SUPPURATIVA TREATED WITH SECUKINUMAB: A CASE REPORT